Analyst consensus rating
Biohaven Analyst Rating: Buy
Direct answer
Biohaven's consensus rating is Buy.
15 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $22.93.
Forecast evidence checked October 27, 2026.
Get free Biohaven email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $15.29
- Average price target
- $22.93
- High price target
- $48.00
- Low price target
- $10.00
- Low target gap
- -34.6%
- Target upside
- +50%
- High target gap
- +213.9%
- Target range width
- 248.5%
- Consensus rating
- Buy
- Analysts
- 15
- Evidence date
- October 27, 2026
- Valid through
- November 3, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Biohaven?
Biohaven has a verified Buy consensus. The same dataset has an average price target of $22.93.
How far are Biohaven's low and high targets from the recorded price?
The low target implies -34.6%, while the high target implies +213.9%.
How many analysts are included in Biohaven's consensus?
The verified consensus includes 15 analysts.
How is Biohaven's target upside or downside calculated?
The average target of $22.93 is divided by the recorded price of $15.29, then one is subtracted to produce +50%. This does not guarantee a future return.
When was Biohaven's analyst forecast verified?
The data was verified on 2026-10-27. The dataset is valid through 2026-11-03.